Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR
Want to see BNR full AI Analyst Report?
BNR Stock Chart & Stats
$23.40
<$0.01(0.06%)
At close: 4:00 PM EST
$23.40
<$0.01(0.06%)
Day’s Range― - ―
52-Week Range$2.95 - $41.72
Previous CloseN/A
Volume1.44K
Average Volume (3M)22.64K
Market Cap
$86.04M
Enterprise Value-$371.17M
Total Cash (Recent Filing)$481.39M
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-51.80
Shares Outstanding8,813,858
10 Day Avg. Volume13,298
30 Day Avg. Volume22,645
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.28
Price to Sales (P/S)0.28
P/FCF Ratio-4.51
Enterprise Value/Market Cap-4.31
Enterprise Value/Revenue-0.69
Enterprise Value/Gross Profit-0.92
Enterprise Value/Ebitda8.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins indicate durable pricing power and attractive unit economics for NGS testing. Margin expansion in 2025 reflects a richer mix toward higher‑margin projects and lower operating costs, supporting longer‑term profitability even if revenue growth is uneven.
Conservative Balance Sheet / Low LeverageVery low debt reduces refinancing and solvency risk, preserving strategic optionality. Coupled with material cash on hand at year‑end, the conservative capital structure supports continued investment in product development and regulatory/clinical activities without immediate debt pressure.
Shifting Mix Into Higher‑value Pharma R&D And Regulatory WinsGrowth in pharma R&D services and regulatory/technology milestones represent structural moves up the value chain: deeper biopharma relationships, proprietary IP and regulatory recognition can secure longer‑duration contracts, higher margins, and differentiated positioning in precision oncology.
Bears Say
Persistent Negative Cash FlowOngoing negative OCF/FCF constrains reinvestment and heightens the need for external financing. Even with improved burn in 2025, consistent cash outflows limit ability to scale sales, fund trials or absorb lumpy project timing, raising execution and liquidity risk over the medium term.
Revenue Softness And Inconsistent Top-line TrendsFlat or declining revenues undermine operating leverage, making it harder to convert high gross margins into sustained net profits. Reliance on lumpy pharma projects and variable hospital adoption increases volatility and slows structural revenue scaling needed for durable profitability.
Ongoing Net Losses And Negative ReturnsPersistent losses erode equity and limit shareholder value creation, often forcing dilution or external funding. Negative ROE and cumulative losses restrict capacity for consistent R&D/sales investment and can impair long‑term competitiveness if profitable scale is not achieved.
Burning Rock Biotech News
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $2.95 and its highest was $41.72 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Burning Rock Biotech Ltd.’s market cap is $86.04M.
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 84 days.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Currently, no data Available
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,813,858 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Currently, no hedge funds are holding shares in BNR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Burning Rock Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.28%
12-Months-Change
Fundamentals
Return on Equity
-9.93%
Trailing 12-Months
Asset Growth
-3.21%
Trailing 12-Months
Company Description
Burning Rock Biotech Ltd.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.